Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 24591145)

1.

Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3.

Dai CY, Chuang WL, Yu ML.

Hepatology. 2014 Dec;60(6):2129-30. doi: 10.1002/hep.27109. Epub 2014 Sep 19. No abstract available.

PMID:
24591145
2.

Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.

Rembeck K, Waldenström J, Hellstrand K, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Lagging M.

Hepatology. 2014 Jun;59(6):2131-9. doi: 10.1002/hep.27009. Epub 2014 Apr 25.

PMID:
24519039
3.

Reply: To PMID 24519039.

Lagging M, Rembeck K, Waldenström J, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Hellstrand K.

Hepatology. 2014 Dec;60(6):2130-1. doi: 10.1002/hep.27108. Epub 2014 Sep 24. No abstract available.

PMID:
24591101
4.

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A.

J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.

PMID:
23301546
5.

Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.

Hai H, Tamori A, Enomoto M, Morikawa H, Uchida-Kobayashi S, Fujii H, Hagihara A, Kawamura E, Thuy le TT, Tanaka Y, Kawada N.

J Gastroenterol Hepatol. 2014 Jan;29(1):201-7. doi: 10.1111/jgh.12376.

PMID:
23980585
6.

Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis.

Bruno S, Mangia A.

J Hepatol. 2013 Jun;58(6):1259. doi: 10.1016/j.jhep.2013.01.024. Epub 2013 Jan 29. No abstract available.

7.

Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis".

Foster GR.

J Hepatol. 2013 Jun;58(6):1260. doi: 10.1016/j.jhep.2013.01.027. Epub 2013 Jan 29. No abstract available.

8.

A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C.

Dai CY, Chuang WL, Yu ML.

Hepatology. 2014 Dec;60(6):2128-9. doi: 10.1002/hep.27096. Epub 2014 Sep 18. No abstract available.

PMID:
24585417
9.

Reply: To PMID 24442928.

Santantonio TA, Fasano M, Sagnelli E.

Hepatology. 2014 Dec;60(6):2129. doi: 10.1002/hep.27100. Epub 2014 Sep 23. No abstract available.

PMID:
24585448
10.

Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.

Lyoo K, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, Bae SH, Choi JY, Choi SW, Shin EC, Yoon SK.

J Clin Virol. 2011 Dec;52(4):363-6. doi: 10.1016/j.jcv.2011.08.006. Epub 2011 Sep 9.

PMID:
21907615
11.

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.

Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE.

J Viral Hepat. 2012 May;19(5):346-52. doi: 10.1111/j.1365-2893.2011.01555.x. Epub 2011 Nov 9.

PMID:
22497814
12.

Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.

Eskesen AN, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O.

Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6. doi: 10.1097/MEG.0b013e3283546efd.

PMID:
22584257
13.

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A.

Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10.

PMID:
21274861
14.

Shorter treatment for hepatitis C genotype 4 may be a possibility.

Iqbal S, Mansour M, Cerulli MA.

South Med J. 2008 Jan;101(1):106. doi: 10.1097/SMJ.0b013e31815d253c. No abstract available.

PMID:
18176306
15.

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ; CHARIOT Study Group.

J Hepatol. 2010 Oct;53(4):616-23. doi: 10.1016/j.jhep.2010.04.024. Epub 2010 Jun 16.

PMID:
20619475
16.

Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.

Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M.

Digestion. 2011;84 Suppl 1:56-61. doi: 10.1159/000333215. Epub 2011 Dec 2.

PMID:
22156487
17.

Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?

Tillmann HL.

J Hepatol. 2013 Mar;58(3):412-4. doi: 10.1016/j.jhep.2012.12.007. Epub 2012 Dec 13. No abstract available.

18.

Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.

Sato K, Yanagisawa M, Hashizume H, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M.

World J Gastroenterol. 2013 Sep 14;19(34):5754-8. doi: 10.3748/wjg.v19.i34.5754.

19.

A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.

Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.

J Infect Chemother. 2014 May;20(5):320-4. doi: 10.1016/j.jiac.2013.11.006. Epub 2014 Jan 27.

PMID:
24477330
20.

Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.

Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K.

Intervirology. 2012;55(4):306-10. doi: 10.1159/000328661. Epub 2011 Aug 25.

PMID:
21865660
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk